Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey

Basit Öğe Kaydı
dc.contributor.authorOzmen, Vahit
dc.contributor.authorAtasoy, Ajlan
dc.contributor.authorGokmen, Erhan
dc.contributor.authorOzdogan, Mustafa
dc.contributor.authorGuler, Nilufer
dc.contributor.authorUras, Cihan
dc.contributor.authorOk, Engin
dc.date.accessioned2024-04-24T17:33:07Z
dc.date.available2024-04-24T17:33:07Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX (R) 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the impact of the Recurrence Score (R) (RS) on treatment decisions and physician perceptions in Turkey. We also studied correlations between RS and routine risk factors. Patients and Methods: Ten academic centers across Turkey participated in this prospective trial. Consecutive breast cancer patients with pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at multidisciplinary tumor conferences. The initial treatment decision was recorded before tumor blocks were sent to the central laboratory. Each case was brought back to tumor conference after receiving the RS result. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classical risk factors were evaluated using univariate and multivariate analyses. Results: Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. The overall rate of change in treatment decision was 33%. Initially, chemotherapy followed by hormonal therapy (CT+HT) was recommended to 92 (56%) of all patients, which decreased to 61 (37%) patients post-RS assay (p<0.001). Multivariate analysis indicated that progesterone receptor (PR) and Ki-67 scores were significantly related to RS. Conclusion: Oncotype DX testing may provide meaningful additional information in carefully selected patients.en_US
dc.identifier.doi10.7759/cureus.522
dc.identifier.issn2168-8184
dc.identifier.issue3en_US
dc.identifier.pmid27081583
dc.identifier.urihttps://doi.org/10.7759/cureus.522
dc.identifier.urihttps://hdl.handle.net/11468/20444
dc.identifier.volume8en_US
dc.identifier.wosWOS:000453611000008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectAdjuvant Treatmenten_US
dc.subjectOncotype Dxen_US
dc.subjectDecision Impacten_US
dc.subjectGenomic Testingen_US
dc.titleImpact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkeyen_US
dc.titleImpact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu